EGFR突变靶向治疗耐药后治疗新选择 2024年1月29日,国产创新药艾帕洛利托沃瑞利单抗(PD-1/CTLA4双抗)联合化疗+/-贝伐治疗非小细胞肺癌(NSCLC)II期研究结果在线发表于《信号转导与靶向治疗》(Signal Transduction and Targeted Therapy,影响因子39.3)。艾帕洛利托沃瑞利单抗...
[7]Jin Y, Shi X, Zhao J, et al. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. Lung Cancer. 2018 Oct;124:110-116. DOI: 10.1016/j.lungcan.2018.07.039 [8] Jakobsen JN, Santoni-Rugiu E, Grauslund M, et al. Concomitant driver mutations i...
血管内皮生长因子和表皮生长因子受体(EGFR)信号通路的双重抑制为提高EFGR靶向治疗的有效性提供了前景。 2024年8月13日,中山大学肿瘤防治中心方文峰、张力共同通讯在Signal Transduction and Targeted Therapy发表题为“Gefitinib (an EGFR tyr...
[1].Fang W, Huang Y, Hong S, et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer[J]. BMC Cancer, 2019, 19(1):595 [2].Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the futu...
2、Zhang Z, et al., Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer, Biomark Res. 2019 Nov 21;7:27. 3、Huanlan Sa,et al., A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell ...
2024年8月13日,中山大学肿瘤防治中心内科张力、方文峰团队牵头开展的“安罗替尼联合吉非替尼对比安慰剂联合吉非替尼一线治疗ⅢB-Ⅳ期EGFR基因突变型非小细胞肺癌患者多中心、随机、双盲、平行对照Ⅲ期临床研究” (FL-ALTER)结果在国际知名期刊《信号转导与靶向治疗》(Signal Transduction and Targeted Therapy)正式发表...
近日,英国伦敦大学学院癌症研究所的科研人员在Nature Communications发表了题为“Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling”的文章。研究团队分析了携带EGFR和TP53共突变的LUAD患者与单一EGFR突变患者对EGFR TKI治疗反应的差异,发现共突变患者更可能...
2、Zhang Z, et al., Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer, Biomark Res. 2019 Nov 21;7:27. 3、Huanlan Sa,et al., A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell ...
EGFR-mutated, MET-amplified advanced non-small-cell lung cancer [J]. Invest New Drugs, 2021, 39(2): 477-87.[5]GUO R, LUO J, CHANG J, et al. MET-dependent solid tumours - molecular diagnosis and targeted therapy [J]. Nat Rev Clin Oncol, 2020, 17(9): 569-87.#医生诊疗笔记# ...
[11]WU S G,SHIH J Y. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer[J]. Mol Cancer,2018,17( 1) : 38. DOI: 10.1186/ s12943-018-0777-1 [12] Ota T,Okabayashi A,Fukuoka M.Rapid and dramatic responses to dabrafenib and trametinib...